Selecting the correct vendors to support your UX project is critical to success. From facilities to recruiting, knowing the right questions to ask, budget constraints, and client needs and expectations will make the selection process smooth and painless.
Back to team page
Kaitlin Carter
Director
Kaitlin (known to many by their nickname Indy) approaches every project with the multidisciplinary lens of 5+ years of experience in both human factors and UX. Their passion lies in human factors studies, ranging from complex drug delivery systems to software as medical device (SaMD). Their research background in linguistic and business anthropology offers clients insight from various industries that can be applied to every research question. Kaitlin has a BA in Cultural Anthropology and an MA in Business and Organizational Anthropology from Wayne State University.



Bold facts
Learn more about

Something unique about you summed up in one sentence

Your favorite part of working at Bold Insight

Do you have a long-term personal or professional goal you'd like to share?

How long have you been in the UX field?

You cannot start the day without doing this...

Your favorite city in the world is...and why?

Your ultimate celebrity dinner party guest list would include:

Any other facts to share?
Read our team’s latest bold insights
Reclassifying diabetes: 3 implications for product design
Recent research suggests that reclassifying diabetes may allow for the development of more targeted diabetes treatments. This could present opportunities to design these treatments to maximize patient safety and experience.
Designing your POS so it’s not a POS
Regardless of whether the interface is intended to be used by a customer (novice) or an employee (expert), the key is to ensure that the POS interface is designed for the intended audience. To do this, organizations should engage users throughout the design process.
FDA’s digital health precertification program emphasizes importance of post-market surveillance
Finding efficient ways to leverage post-market surveillance data to inform product development at an institutional level will be key for SaMD manufacturers seeking FDA precertification.